Monashee Investment Management LLC Immunovant, Inc. Transaction History

Monashee Investment Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $908,100 - $1.31 Million	30,000 Added 42.86%	100,000 $3.23 Million
Q4 2023 Feb 12, 2024	SELL	$31.31 - $44.19 $3.13 Million - $4.42 Million	-100,000 Reduced 58.82%	70,000 $2.95 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $3.15 Million - $6.79 Million	170,000 New	170,000 $6.53 Million
Q4 2020 Feb 11, 2021	SELL	$36.36 - $52.71 $1.82 Million - $2.64 Million	-50,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $1.13 Million - $1.95 Million	50,000 New	50,000 $1.76 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monashee Investment Management LLC with notifications on news.